Cellnovo Eyes Year-End Clearance For Mobile Diabetes System
This article was originally published in The Gray Sheet
Executive Summary
Cellnovo is on track to receive 510(k) clearance and begin a U.S. launch by year-end for its mobile diabetes management system, aided by a recently completed $48 million financing round, according to the company.
You may also be interested in...
News In Brief
Optos buys Opko’s eye instrument unit
News In Brief
Optos buys Opko’s eye instrument unit
Remote Chronic Care Devices Should Target The Sickest Patients, CMS Official Says
Remotely monitored health information that a clinician never reviews does not have much value.